<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101189</url>
  </required_header>
  <id_info>
    <org_study_id>AC-078-105</org_study_id>
    <nct_id>NCT03101189</nct_id>
  </id_info>
  <brief_title>A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects</brief_title>
  <official_title>A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-dose ACT-541468 in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      So far, ACT-541468 has been studied mainly in Caucasian subjects. The present study will&#xD;
      bridge results obtained in Caucasian subjects to those in Japanese subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Actual">April 26, 2017</completion_date>
  <primary_completion_date type="Actual">April 24, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ACT-541468</measure>
    <time_frame>From Day1 pre-dose to 48 hours after the last dose on Day 5</time_frame>
    <description>The geometric mean Cmax values will be calculated based on pharmacokinetic (PK) blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curves during a dosing interval [AUC(0-24)] of ACT-541468</measure>
    <time_frame>From Day1 pre-dose to 48 hours after the last dose on Day 5</time_frame>
    <description>The geometric mean AUC(0-24) values will be calculated based on PK blood sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax) of ACT-541468</measure>
    <time_frame>From Day1 pre-dose to 48 hours after the last dose on Day 5</time_frame>
    <description>The median tmax values will be calculated based on PK blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life [t(1/2)] of ACT-541468</measure>
    <time_frame>From Day1 pre-dose to 48 hours after the last dose on Day 5</time_frame>
    <description>The geometric mean t(1/2) values will be calculated based on PK blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curves from time 0 to 8 h [AUC(0-8)]</measure>
    <time_frame>From Day1 pre-dose to 48 hours after the last dose on Day 5</time_frame>
    <description>The geometric mean AUC(0-8) values will be calculated based on PK blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to Day 7 (end of study)</time_frame>
    <description>The percentage of subjects with treatment-emergent adverse events will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events leading to premature discontinuation of study treatment</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>The number of subjects who prematurely discontinued the study treatment due to an adverse event will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any clinical relevant findings in ECG variables</measure>
    <time_frame>Up to Day 7 (end of study)</time_frame>
    <description>The number of subjects with any treatment-emergent electrocardiogram (ECG) abnormalities will be reported</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>ACT-541468 (25 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Japanese and 8 Caucasian subjects will receive 25 mg (1 capsule) of ACT-541468 once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT-541468 (50 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Japanese and 8 Caucasian subjects will receive 50 mg (2 capsules) of ACT-541468 once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 Japanese / 2 Caucasian subjects will receive 1 placebo capsule to match subjects in the ACT-541468 (25 mg) group and 2 other Japanese / 2 Caucasian subjects will receive 2 placebo capsules to match subjects in the ACT-541468 (50 mg) group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-541468</intervention_name>
    <description>Capsule</description>
    <arm_group_label>ACT-541468 (25 mg)</arm_group_label>
    <arm_group_label>ACT-541468 (50 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form;&#xD;
&#xD;
          -  Healthy male and female subjects aged between 20 and 50 years (inclusive) at&#xD;
             screening;&#xD;
&#xD;
          -  Negative serum pregnancy tests at screening and negative urine pregnancy test at Day 1&#xD;
             for women of childbearing potential and agreement to use a reliable method of&#xD;
             contraception for at least 90 days after last study drug intake;&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 26.0 kg/m2 (inclusive) at screening;&#xD;
&#xD;
          -  Healthy on the basis of physical examination, cardiovascular assessments and&#xD;
             laboratory tests;&#xD;
&#xD;
          -  Caucasian or Japanese ethnicity.&#xD;
&#xD;
        Japanese subjects only:&#xD;
&#xD;
          -  must be of native Japanese descent (all parents/grandparents of Japanese descent);&#xD;
&#xD;
          -  must not have been away from Japan for more than 10 years (at screening visit);&#xD;
&#xD;
          -  lifestyle should not have changed significantly since relocation from Japan.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication to the study treatments;&#xD;
&#xD;
          -  History or clinical evidence of any disease or medical / surgical condition or&#xD;
             treatment, which may put the subject at risk of participation in the study or may&#xD;
             interfere with the absorption, distribution, metabolism or excretion of the study&#xD;
             treatments;&#xD;
&#xD;
          -  History of narcolepsy or cataplexy or modified Swiss narcolepsy scale total score &lt; 0;&#xD;
&#xD;
          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
             full participation in the study or compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clemens Muehlan</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>Japanese</keyword>
  <keyword>pharmacokinetics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

